

Leveraging Structure-Based Drug Design Technologies to Accelerate Drug Candidate Generation.

Graham Johnson, Chief Research Officer, Rib-X Pharmaceuticals, Inc., New Haven, CT

Rib-X Pharmaceuticals is a small molecule drug discovery and development company focused on the structure-based design and synthesis of new classes of antibiotics. The Company's drug discovery strategy exploits its proprietary high-resolution crystal structure of the bacterial ribosome 50S subunit. Validating its initial business model, Rib-X has already generated several clinical candidates from its most advanced R -01 discovery program. These compounds, which we have termed "designer oxazolidinones", are orally active with attributes appropriate for either the hospital Gram-positive or community acquired pneumonia marketplace. In this presentation we will describe the genesis of this program and highlight how we applied our structural and computational tools to direct and accelerate our progress toward identifying several clinical candidates.